USANA Health Sciences (NYSE:USNA) Releases Q3 2021 Earnings Guidance

USANA Health Sciences (NYSE:USNA) issued an update on its third quarter 2021 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $1.280-$1.330 for the period, compared to the Thomson Reuters consensus estimate of $1.440. The company issued revenue guidance of $265 million-$270 million, compared to the consensus revenue estimate of $303.24 million.USANA Health Sciences also updated its FY 2021 guidance to $5.800-$6.000 EPS.

Shares of NYSE USNA traded up $0.90 during trading hours on Friday, hitting $89.93. The stock had a trading volume of 83,752 shares, compared to its average volume of 89,432. The company has a market capitalization of $1.80 billion, a P/E ratio of 13.56 and a beta of 0.85. The firm’s 50-day moving average price is $95.63 and its two-hundred day moving average price is $98.53. USANA Health Sciences has a 52 week low of $72.03 and a 52 week high of $107.85.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, July 27th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.78 by $0.09. The firm had revenue of $336.84 million during the quarter, compared to analysts’ expectations of $340.20 million. USANA Health Sciences had a return on equity of 33.65% and a net margin of 11.09%. Equities research analysts anticipate that USANA Health Sciences will post 6.31 earnings per share for the current fiscal year.

Separately, Zacks Investment Research lowered USANA Health Sciences from a hold rating to a sell rating in a report on Tuesday.

In other USANA Health Sciences news, Director John Turman Fleming sold 300 shares of the stock in a transaction on Monday, August 30th. The stock was sold at an average price of $97.26, for a total transaction of $29,178.00. Following the completion of the transaction, the director now directly owns 851 shares in the company, valued at $82,768.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frederic J. Winssinger sold 926 shares of the stock in a transaction on Thursday, July 29th. The stock was sold at an average price of $99.08, for a total value of $91,748.08. Following the transaction, the director now owns 2,516 shares of the company’s stock, valued at $249,285.28. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 3,435 shares of company stock valued at $331,837. Corporate insiders own 0.21% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

Featured Article: Why are analyst ratings important in trading stocks?

Earnings History and Estimates for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.